2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 869

Utility of Carotid Ultrasound Compared to Framingham Risk Score in Predicting Cardiovascular Mortality in Rheumatoid Arthritis
Abstract Number: 870

Detection of Left Ventricular Regional Function in Rheumatoid Arthritis Patients without Cardiac Symptons, As Assessed By Feature Tracking Cardiac Magnetic Resonance Imaging
Abstract Number: 871

Coronary Microvascular Dysfunction in Rheumatoid Arthritis Compared to Diabetes Mellitus in Patients without Obstructive Coronary Artery Disease
Abstract Number: 872

Myocardial Abnormalities Improve in RA Patients Treated Actively – a Cardiac MRI Follow-up Study
Abstract Number: 873

Type I High-IFN Gene Signature in Associated with Higher Essdai at Enrollmment and Follow-up in the Prospective Multicenter Assess Cohort of 395 Patients
Abstract Number: 874

Effect of Rituximab on a Salivary Gland Ultrasound Score in Primary Sjögren’s Syndrome: Results of Multicentre Double-Blind Randomised Controlled Trial Sub-Study
Abstract Number: 875

Serum Autoantibody Profiling of Primary Sjoegren’s Syndrome Patients Reveals Novel Biomarkers Associated with the Disease, Disease Activity, and Clinical Response to VAY736
Abstract Number: 876

Epidemiologic Subsets Drive a Differentiated Clinical and Immunological Presentation of Primary Sjögren Syndrome: Analysis of 9302 Patients from the Big Data International Sjögren Cohort
Abstract Number: 877

Modification of the Classification Criteria for Primary Sjögren Syndrome: An International Vignette Survey
Abstract Number: 878

Diagnosis of Salivary Gland Lymphoma in Sjogren’s Syndrome Utilizing Ultrasound-Guided Core Needle Biopsies
Abstract Number: 879

Association of Venous Thromboembolism with Spondyloarthopathies Among Hospitalized Patients – Data from National Inpatient Sample
Abstract Number: 880

Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study
Abstract Number: 881

Ustekinumab Is Superior to TNF Inhibitor Treatment in Resolving Enthesitis in Psa Patients with Active Enthesitis- Results from the Enthesial Clearance in Psoriatic Arthritis Study
Abstract Number: 882

A New Model of Care for Improving Early Rheumatology Access of Psoriatic Arthritis Patients
Abstract Number: 883

The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Ankylosing Spondylitis: A General Population-Based Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].